Acquired Dermal Macular Hyperpigmentation: An Update

Keshavamurthy Vinay1, Anuradha Bishnoi1, Divya Kamat1

  • 1Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Insights

Acquired dermal macular hyperpigmentation (ADMH) is a unifying term for several skin conditions. This review covers recent advances in understanding and treating these challenging pigment disorders.

Area of Science:

  • Dermatology
  • Pathology

Background:

  • Acquired dermal macular hyperpigmentation (ADMH) encompasses conditions like lichen planus pigmentosus and Riehl's melanosis.
  • These disorders present with pigmented macules and interface dermatitis, often lacking a clear inflammatory phase.
  • Their nomenclature and etiology have been debated, complicating research and treatment.

Purpose of the Study:

  • To provide a comprehensive review of recent advancements in Acquired Dermal Macular Hyperpigmentation (ADMH).
  • To consolidate understanding of related conditions under a single, unifying term.
  • To facilitate future research and therapeutic trials for ADMH.

Main Methods:

  • Literature review of recent studies on ADMH and related conditions.
  • Analysis of clinicopathological similarities and differences.
  • Synthesis of current understanding regarding nomenclature and etiology.

Main Results:

  • ADMH is proposed as an umbrella term for previously distinct disorders.
  • Shared features include pigmented macules and interface dermatitis with pigment incontinence.
  • Recent consensus supports a unifying nomenclature for research and clinical trials.

Conclusions:

  • A unified approach to ADMH is crucial for advancing research and treatment.
  • Understanding recent advances is key to managing these challenging pigmentary conditions.
  • ADMH facilitates a clearer framework for studying and treating lichen planus pigmentosus, Riehl's melanosis, and ashy dermatosis.